Medigene : Präsentation zur Einstellung des MDG1021 Entwicklungsprogramms

Corporate Update - MDG1021 discontinuation

28 January 2021

Forward looking statements disclaimer

All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. The information contained in this presentation should be considered in the context of the circumstances prevailing at that time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

This presentation may contain certain forward-looking statements and forecasts which relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the Company's business, financial condition and results of operations. The terms

"anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will",

"would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of the Company's strategy and its ability to further grow, risks associated with the development and/or approval of the Company's products candidates, ongoing clinical trials and expected trial results, technology changes and new products in the Company's potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. While we always intend to express our best judgment when we make statements about what we believe will occur in the future, and although we base these statements on assumptions that we believe to be reasonable when made, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of our control and could cause our actual results to differ materially from those we thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. We do not undertake, and specifically decline, any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.

2

Medigene - Innovative T cell therapies for solid tumors

Focus on innovative T cell-based immunotherapies

Excellence in TCR discovery

Healthy TCR repertoires screened: Scale & speed

Optimal TCR properties: Avidity & specificity

Antigen targets of choice

Excellence in functional enhancements of therapeutic T cells

Resistance to inhibitory tumor microenvironment

Augmented metabolic fitness

Advancing clinical development from liquid to solid cancers

Prof. Dolores J. Schendel

CEO & CSO

3

Key information

Company

Martinsried, near Munich, Germany

~100 employees at end 2020

~€35.8 m cash*

COVID-19 Situation Update

Personnel

Work from home and on-site

Partner Programs

Continued R&D activities at Medigene support partners

Clinical Trials

No COVID-19 related delays in Germany

*As of 30 Sep 2020; **At close 27 January 2021

Listing

Frankfurt Stock Exchange (MDG1)

~24.6 m shares outstanding ~€110 m market cap**

Outlook

MDG1011 Phase I/II trial anticipating 3rd dose cohort to be dosed in Q1 2021

Publication of clinical and preclinical data at conferences

bluebird bio: MAGE-A4TCR-T + enhancer in preclinical development

Roivant/Cytovant: DC vaccine progressing towards clinic

4